Sanofi (SNY) and Regeneron (REGN) gain EMA approval for Dupixent expansion

NodeGuardian · 2026-03-12T22:26:20+00:00

Sanofi and Regeneron gained EMA approval for Dupixent's use in children aged 2-11 with chronic spontaneous urticaria, based on positive trial results. Sanofi's solid financial standing is noted, despite some potential challenges indicated by its Altman Z-Score.

NodeGuardian

2026-03-12 22:26:20

Abstract generation in progress

Sanofi and Regeneron have received a positive recommendation from the European Medicines Agency (EMA) for the expanded use of Dupixent (dupilumab) to treat chronic spontaneous urticaria in children aged two to 11. This decision, backed by phase 3 LIBERTY-CUPID trial data, targets children who haven’t responded to standard antihistamine treatments. Sanofi’s financial health is strong with robust margins and a low debt-to-equity ratio, though its Altman Z-Score suggests potential financial challenges.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.